Spanish HIV Documentary Sells Two Tickets Despite €317k Subsidy

Two Tickets Sold: The Spanish HIV Documentary That No One Saw

A single tweet lit the fuse. In a theater on Madrid’s Gran Vía, Eduardo Casanova’s documentary about HIV was screening, and the box office numbers were laughable: two tickets sold for that day’s session and just one for the next. The message, shared with irony (“Who is bothered? By what?”), became the starting point for a discussion that, as almost always, drifted toward public funding. Because the issue of the documentary—referred to in the conversation as Enferma—stopped being a matter of cinematic taste and turned into an improvised audit of cultural subsidies.

How Much It Cost and Who Paid

The data that fueled the crossfire wasn’t the number of viewers, but the figure circulating in the thread, allegedly found in public records: €317,000 in subsidies. From there, the analysis peine. It was explained that part of the financing doesn’t come through direct channels, but via tax deductions: production companies can reduce up to 30% in Corporate Income Tax, and it is common to use temporary economic interest associations (UTEs) that allow companies outside the sector to invest and deduct up to 120% of their contribution. Translated: if you owe €10,000 to the tax agency, investing €8,333 in the project means you pay nothing. In this scheme, the commercial success of the film matters little.

Box Office Failure, Number by Number

The first week’s numbers didn’t help sustain the narrative of a cultural phenomenon. The premiere grossed €2,900 across twenty cinemas, averaging €138 per venue. The cumulative total reached €11,000, driven mainly by the Madrid premiere, which had its own fanfare. With these figures, pulling from theaters was a matter of days. Comparisons with other recent documentaries weren’t flattering either: one about ETA case prescriptions had only 6 viewers and €29 in box office, reminding some that double standards are a national sport.

The Cross-Subsidy Argument

The most resonant thesis was that the business of subsidized cinema doesn’t depend on the audience. The film industry, it was argued, is practically the only one maintaining state and regional frameworks, plus specific regulations, to write off almost everything until no taxes are paid. And the problem, it was added, isn’t partisan: whoever governs, the machine distributing money among friends keeps running the same way, whether for an HIV documentary, an ETA one, or any other product. The conclusion floating in the air was that box office failure isn’t a failure for anyone: it is simply the expected result of a model where the viewer is merely a bystander.

The Audience That Doesn’t Show Up

Beyond the accounts, the issue shifted to content. There was debate on whether the documentary addresses HIV stigma or if it is merely talentless provocation. Some argued that the disease most researched and raised awareness for over decades doesn’t need additional victimhood, while others recalled conditions like cancer or neurodegenerative diseases have fewer platforms. It was also suggested the documentary might end up screened in schools for awareness, which some read as a backdoor justification for the subsidy. The scene of the empty cinema, in any case, became the symbol of the whole mess.

---

In the end, the anecdote that sums up the issue isn’t the two tickets sold. It’s that, with those numbers, the film remained in theaters weeks later. Someone, in some office, had decided it was worth keeping.